Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
01-03 May, 2026
Not Confirmed
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
03-06 May, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
01-03 May, 2026
Industry Trade Show
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
03-06 May, 2026
Digital content

08 Apr 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260408549494/en/Pilatus-Biosciences-to-Present-New-Data-Highlighting-Sex-Specific-Efficacy-of-CD36-Targeting-Antibody-in-Colorectal-Cancer-at-AACR-2026

12 Mar 2026
// BUSSINESSWIRE
https://www.businesswire.com/news/home/20260308705893/en/Pilatus-Biosciences-Announces-First-Patient-Dosed-in-Phase-1-Trial-of-First-in-Class-Metabolic-Checkpoint-Antibody-PLT012-in-Solid-Tumors

19 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260219271062/en/Pilatus-Biosciences-Receives-FDA-Fast-Track-Designation-for-Metabolic-Checkpoint-Inhibitor-PLT012-in-Hepatocellular-Carcinoma

15 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251212767192/en/Pilatus-Biosciences-Announces-FDA-Clearance-of-IND-Application-for-PLT012-a-First-in-Class-Anti-CD36-Metabolic-Checkpoint-Antibody-in-Solid-Tumors

30 Oct 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/pilatus-biosciences-to-present-new-preclinical-data-highlighting-plt012s-ability-to-induce-durable-anti-tumor-immunity-through-immunometabolic-reprogramming-of-the-tumor-microenvironment-at-sitc-2025-annual-meeting-302599643.html

14 Oct 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251014693867/en/Pilatus-Biosciences-Announces-Issuance-of-Foundational-Global-Patent-Covering-Novel-CD36-Targeted-Immunotherapy
ABOUT THIS PAGE